Linden J
Mol Pharmacol. 1984 Nov;26(3):414-23.
(-)-N6-(R-4-Hydroxyphenylisopropyl)adenosine (HPIA) was iodinated with NaI and trace 125I. Mono- and diiodinated reaction products and the starting material were separated by high pressure liquid chromatography and the structures of the reaction products were verified by NMR. (-)-N6-(R-Phenylisopropyl)adenosine (PIA), IHPIA, and I2HPIA decreased rat atrial contractility with ED50 values of 24, 28, and 33 nM, respectively. The contractile effects of these compounds were competitively blocked by theophylline (KI = 7.9 microM), but were not affected by adenosine deaminase. IHPIA also inhibited (-)isoproterenol-stimulated cyclic AMP accumulation in adipocytes with an ED50 (10 nM) and to an extent (83%) nearly identical to PIA. [125I]HPIA prepared using carrier-free 125I bound to adenosine receptors on membranes from rat cerebral cortex, adipocyte ghosts, and heart ventricles. Binding was inhibited stereospecifically by PIA and by other adenosine analogues and alkylxanthines. The KD of [125I]HPIA determined kinetically using brain membranes at 21 degrees was 0.94 nM (K1 = 2.55 X 10(7) M-1 min-1; K-1 = 0.024 min-1) in good agreement with the equilibrium determination of 1.94 nM. The density of adenosine receptors in brain membranes was found to be 871 fmol/mg of protein. When normalized to protein, the density of receptors in heart membranes and adipocyte ghosts, respectively, was found to be 39- and 2.3-fold less than in brain membranes. We conclude that [125I]HPIA can be rapidly synthesized and purified, binds to adenosine R-sites and is an agonist radioligand resistant to adenosine deaminase. Computer modeling of the equilibrium binding resulting from the use of mixed stereoisomers of a radioligand indicates that the combined use of (-)[125I]HPIA and (+)[125I]HPIA would result in the generation of nonlinear Scatchard plots.
(-)-N6-(R-4-羟基苯异丙基)腺苷(HPIA)用碘化钠和微量125I进行碘化。单碘和二碘反应产物以及起始原料通过高压液相色谱法分离,反应产物的结构通过核磁共振进行验证。(-)-N6-(R-苯异丙基)腺苷(PIA)、IHPIA和I2HPIA降低大鼠心房收缩力,其半数有效剂量(ED50)值分别为24、28和33 nM。这些化合物的收缩作用被茶碱竞争性阻断(抑制常数KI = 7.9 microM),但不受腺苷脱氨酶影响。IHPIA还抑制(-)异丙肾上腺素刺激的脂肪细胞中环磷酸腺苷(cAMP)的积累,其半数有效剂量(ED50)为10 nM,抑制程度(83%)与PIA几乎相同。使用无载体125I制备的[125I]HPIA与大鼠大脑皮层、脂肪细胞膜和心室膜上的腺苷受体结合。PIA以及其他腺苷类似物和烷基黄嘌呤可立体特异性地抑制这种结合。在21摄氏度下使用脑膜动力学测定的[125I]HPIA的解离常数(KD)为0.94 nM(正向速率常数K1 = 2.55×10^7 M^-1 min^-1;逆向速率常数K-1 = 0.024 min^-1),与平衡测定的1.94 nM结果吻合良好。发现脑膜中腺苷受体的密度为871 fmol/mg蛋白质。以蛋白质进行归一化后,发现心脏膜和脂肪细胞膜中受体的密度分别比脑膜中的低39倍和2.3倍。我们得出结论,[125I]HPIA可以快速合成和纯化,与腺苷R位点结合,并且是一种对腺苷脱氨酶有抗性的激动剂放射性配体。对使用放射性配体的混合立体异构体产生的平衡结合进行计算机建模表明,联合使用(-)[125I]HPIA和(+)[125I]HPIA将导致产生非线性Scatchard图。